Form 4 for BRTX BioRestorative Therapies, Inc.
Accepted 2023-03-22 00:00:00 ET · period of report 2023-03-20 · accession 0001021771-23-000028 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-22 | 2023-03-20 | BRTX | Silva Francisco | VP of Research, Development, Dir, 10% | F - Tax | $2.92 | -6,729 | 158.9K | -4% | -$19.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-20 | F | D | 6,729 | $2.92 | 158,943 | D | — | — | (F2) Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024. |